Search This Blog

Thursday, July 29, 2021

Vertex Reports Second-Quarter 2021 Financial Results

 - Product revenues of $1.79 billion, an 18% increase compared to Q2 2020 -

- Company raises full-year 2021 guidance for product revenues to $7.2 to $7.4B - 

- Phase 3 study of next-in-class triple combination for CF to begin in the second half of 2021; multiple additional clinical milestones across the pipeline expected in the next 6 to 9 months -

https://www.businesswire.com/news/home/20210729006087/en/Vertex-Reports-Second-Quarter-2021-Financial-Results

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.